Overview

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

Status:
Terminated

Trial end date:
2003-05-01

Target enrollment:

Participant gender:

Summary

Triple antiviral therapy with peg-interferon-alfa/ribavirin+amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to a standard interferon/ribavirin combination. Patients with hepatitis C virus infection were eligible if they had failed to respond to a single previous 24 week cycle of interferon/ribavirin combination therapy. Non-response was defined as persistent HCV RNA in the serum during the last month of treatment. This study tested the efficacy and safety of pegylated interferon alfa-2b with ribavirin and amantadine or a placebo for 48 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborator:

Schering-Plough

Treatments:

Amantadine
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin